Clinical Trial Update: A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II study of oral JAK1/JAK2 inhibitor INC424 in adults with relapsed/refractory classical Hodgkin's lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• INC424 (nilotinib)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED